Month: September 2025

The GEO Group (GEO) – A Renewal and Two New Contracts

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, September 17, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contracts. The  Florida Department of Corrections has issued Notices of Intent to Award three managed-only contracts to GEO for the assumption of management and support services at the 985-bed Bay Correctional and Rehabilitation Facility and the 1,884-bed Graceville Correctional and Rehabilitation Facility and for the continuation of management and support services at the 985-bed Moore Haven Correctional and Rehabilitation Facility.

Details. The three contracts are expected to have an initial term of three years, effective  July 1, 2026, with unlimited two-year renewal option periods. On a combined basis, the three contracts are expected to generate approximately  $130 million in annualized revenues, including approximately  $100 million in new incremental annualized revenues for GEO. While the new contracts will not begin until next year, the new awards reflect GEO’s ability to provide the services demanded by its government partners, in our view.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – Activist Shareholder Calls for Strategic Review

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, September 17, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Call For A Review. In an amended Schedule 13D filing, investor Lakeview Opportunity Fund has communicated its views on the Company to the CVG management and Board on opportunities for value creation, including through a review process that explores strategic alternatives, including a sale of the Company.

Who Is Lakeview? With Managing Partner Ari Levy, Lakeview is a concentrated and opportunistic multi-strategy fund. The Fund focuses on underfollowed or ignored market areas, such as small and mid-cap value equities, niche Wall Street vehicles, options, and selective shareholder activism, where Lakeview helps companies, generally trading at significant discounts to private market value, unlock shareholder value.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Nvidia Faces Setback as China Reportedly Bans AI Chips

Posted on by slightbourne@noblecapitalmarkets.com

Nvidia, the world’s leading producer of artificial intelligence chips, is facing fresh uncertainty in one of its most important markets after reports that China has instructed domestic technology firms to stop using its products. According to sources familiar with the matter, Beijing’s Cyberspace Administration has urged major players, including TikTok parent company ByteDance and e-commerce giant Alibaba, to halt purchases of Nvidia’s RTX Pro 6000D chips. The processors were designed specifically for China after earlier restrictions limited the sale of more advanced models.

The development marks another escalation in the ongoing technology rivalry between the United States and China. Washington has already imposed limits on the export of advanced semiconductors to China, citing national security concerns. Last month, the Trump administration struck a deal with Nvidia that allowed its H20 server chips to be sold in the country under strict conditions, with a portion of sales revenues redirected to the U.S. government. However, Beijing’s reported response suggests a determination to reduce reliance on American hardware while accelerating investment in domestic alternatives.

Nvidia has long described its business in China as unpredictable, with company leaders acknowledging the volatility of operating amid geopolitical tensions. This latest setback follows news earlier in the week that Chinese regulators have launched an antitrust investigation into Nvidia’s $6.9 billion acquisition of Mellanox, an Israeli data center networking firm. The probe highlights Beijing’s willingness to scrutinize foreign acquisitions and could add further pressure to Nvidia’s strategic plans in the region.

Despite the challenges in China, Nvidia continues to expand globally at an aggressive pace. During a high-profile U.S. state visit to the U.K., the company announced £11 billion ($15 billion) in investment toward British artificial intelligence infrastructure. The move signals Nvidia’s intention to diversify its growth beyond Asia while deepening ties with Europe’s rapidly expanding AI sector. Other major American technology companies, including Microsoft, Google, and Salesforce, have announced similar multibillion-dollar AI commitments in the U.K., reflecting broader industry momentum.

China, however, remains a key focus for the global AI market. The country’s enormous tech ecosystem, vast consumer base, and strong government backing for artificial intelligence research make it one of the most competitive environments in the world. For Nvidia, exclusion from this market could slow growth and open the door for local competitors to capture share. At the same time, U.S. policy continues to shape the availability of high-performance chips abroad, adding layers of complexity for global semiconductor leaders.

The reported ban underscores the shifting dynamics of the U.S.-China tech rivalry and how quickly geopolitical tensions can reshape business strategies. While Nvidia remains dominant in AI chip innovation, its position in China has transformed from a driver of growth to a source of risk. The coming months will determine whether the company can adapt to the changing environment and preserve its competitive edge in the face of growing political and economic headwinds.

Who Will Own TikTok? U.S. Investors Line Up for $60B Deal

Posted on by slightbourne@noblecapitalmarkets.com

TikTok’s uncertain future in the United States has entered a decisive phase, with a handful of powerful investors lining up to buy a stake in the platform as political pressure mounts.

The Chinese-owned app, run by parent company ByteDance, has been at the center of U.S. scrutiny for years over concerns about data security and influence from Beijing. What began with executive orders and court battles during the Trump administration has evolved into a bipartisan push to either ban TikTok or force a sale of its U.S. operations.

Earlier this year, the U.S. Supreme Court upheld the Protecting Americans from Foreign Adversary Controlled Applications Act (PAFACA), also known as the “TikTok ban.” That ruling seemed to seal the app’s fate. On January 19, TikTok briefly shut down U.S. operations before swiftly returning less than 12 hours later, citing new efforts by President Trump to keep the platform alive.

Trump has since extended TikTok’s reprieve multiple times, most recently postponing enforcement of the ban for 75 days while talks continue. His stated goal: to create “TikTok America,” a structure that splits ownership roughly 50-50 between ByteDance and a U.S.-backed consortium of investors. ByteDance would retain just under 20%.

Reports suggest potential buyers include some of the biggest names in tech and finance. Oracle, Silver Lake, and Andreessen Horowitz are among those positioned to oversee operations. Meanwhile, real estate billionaire Frank McCourt has assembled “The People’s Bid for TikTok,” backed by Project Liberty, Guggenheim Securities, and the law firm Kirkland & Ellis. Their pitch emphasizes transparency, privacy, and open-source technology.

Other bids are also emerging. Jesse Tinsley, CEO of Employer.com, announced a $30 billion all-cash offer through an American investor consortium. At the same time, CFRA Research estimates TikTok’s U.S. valuation could climb to as high as $60 billion if a sale moves forward.

TikTok’s fight for survival highlights just how central the platform has become in American life. With more than 150 million U.S. users—many of them young creators and small businesses—the app represents both cultural clout and enormous advertising potential. For Washington, though, it represents a potential national security risk.

The drama has unfolded against a backdrop of shifting political positions. Trump, who initially championed a ban in 2020, reversed course late last year, signaling a willingness to strike a deal that preserves the platform. The Biden administration’s earlier support of legislation against TikTok underscores that this is not simply a partisan issue, but a broader debate about data sovereignty and global tech power.

As negotiations continue, TikTok’s future remains uncertain. Whether it becomes “TikTok America” under new ownership, or faces fresh legal hurdles, will determine if one of the world’s most popular apps can remain a fixture in U.S. digital life. For now, investors, regulators, and millions of users are watching closely as the clock ticks down.

Release – Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Posted on by slightbourne@noblecapitalmarkets.com

September 15, 2025

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants

BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,764,710 shares of its common stock at a purchase price of $1.70 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share that are exercisable upon issuance and will expire twenty-four months from the effective date of the registration statement covering the resale of the shares of common stock issuable upon exercise of the unregistered warrants.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company, were approximately $4.7 million. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be approximately $8.3 million. No assurance can be given that any of such short-term warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The common stock (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-271883) that was declared effective by the Securities and Exchange Commission (the “SEC”) on May 26, 2023. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering were filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Forward-Looking Statements

The information in this press release includes “forward-looking statements.” Any statements other than statements of historical fact contained herein, including statements as to the intended use of net proceeds from the offering, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology.

Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

Why Gold’s $3,700 Breakout Could Signal a Bigger Move Higher

Posted on by slightbourne@noblecapitalmarkets.com

Gold surged past $3,700 an ounce for the first time in history on Tuesday, as investors doubled down on expectations that the Federal Reserve will cut interest rates this week and possibly keep easing into 2026.

The rally reflects a powerful mix of falling Treasury yields, political pressure on the Fed, and growing concerns that government debt is no longer a safe haven. The U.S. dollar dropped to its weakest level in more than 10 weeks, further boosting gold’s appeal.

Markets have already priced in a rate cut at this week’s Fed meeting, but the real focus is on the central bank’s quarterly economic projections and Chair Jerome Powell’s comments in the post-decision press conference. A series of weak labor market reports and stable inflation readings have strengthened the case for further cuts this year. Since gold does not pay interest, lower rates typically increase its attractiveness compared to bonds.

The political backdrop is also fueling the rally. President Donald Trump has openly pressured the Fed to move faster on monetary easing and has pushed to remove Governor Lisa Cook. Meanwhile, Stephen Miran, a senior economic advisor in the administration, is expected to join the central bank as soon as Tuesday. These developments have reinforced market expectations that monetary policy will stay accommodative in the months ahead.

So far this year, gold has climbed more than 40%, outperforming major assets like the S&P 500. The metal recently surpassed its inflation-adjusted peak from 1980, cementing its status as the safe-haven asset of choice during a time of uncertainty. Central bank buying and strong inflows into exchange-traded funds have added fuel to the rally.

Analysts warn that the move may only be the beginning. Goldman Sachs has suggested that if just 1% of privately held U.S. Treasuries were reallocated into gold, prices could surge toward $5,000 an ounce. For investors wary of ballooning government debt in the U.S., Europe, and beyond, gold has become the natural alternative.

Other precious metals have also seen movement: silver rose to its highest price in 14 years, while platinum and palladium slipped.

With gold setting fresh records and momentum accelerating, markets are now watching whether the Fed’s tone confirms what traders already believe: that a new era of monetary easing has begun. If so, the path toward even higher levels of gold could already be set.

For more context on why investors are shifting away from government debt and piling into gold, read our in-depth analysis from last week here.

Release – Conduent Integrates AI Technologies to Modernize Government Payments, Combat Fraud and Improve Customer Experiences for Beneficiaries

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CNDT

September 16, 2025

Government Corporate

Successfully completed AI pilot with Microsoft – now live – boosts fraud detection

FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, is embedding generative AI (GenAI) and other advanced AI technologies into its suite of solutions for state and federal agencies. These technologies aim to improve the disbursement of critical government benefits, enhance the citizen experience, and fortify fraud prevention across major aid programs like Medicaid and the Supplemental Nutrition Assistance Program (SNAP).

As part of a recently completed GenAI pilot with Microsoft – originally announced in 2024 and now fully deployed – Conduent has significantly increased its fraud detection capacity for its largest open-loop payment card programs. Because these cards can be used at a wide range of merchants, monitoring for fraud is particularly complex. Leveraging AI, a small team of specialists can now surveil tens of thousands of accounts for suspicious activity, including identity theft and account takeover with significant improvement in accuracy. This capability is in the process of being scaled to other payment card programs.

Following the pilot’s success, Conduent is now seeking to apply similar AI methodologies to help detect and prevent fraud in Medicaid and closed-loop EBT cards, including SNAP benefits – helping safeguard usage at approved retailers. A leader in government payment disbursements, Conduent currently supports electronic payments for public programs in 37 states.

“As states adapt to evolving budget constraints and eligibility requirements, AI can empower agencies to reduce fraud and improper payments while improving service delivery,” said Anna Sever, President, Government Solutions at Conduent. “With decades of experience supporting critical government programs, Conduent is deepening its investment in AI to expand these gains across multiple programs.”

Transforming Customer Support with AI

Conduent is also deploying AI to drive improvements in the contact center experience for public benefit recipients. A standout example is the Conduent GenAI-powered capability that equips agents with instant access to accurate, program-specific information – reducing call handling times.

Conduent provides U.S. agencies with solutions for healthcare claims administration, government benefit payments, eligibility and enrollment, and child support. Visit Conduent Government Solutions to learn more.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

Neil Franz

Conduent

neil.franz@conduent.com

+1-240-687-0127

Sean Collins

Conduent

Sean.Collins2@conduent.com

+1-310-497-9205

Release – Snail Games Alongside Frozen Way Games Strengthens Global Market Presence With Honeycomb: The World Beyond at Tokyo Game Show 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SNAL

September 16, 2025 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced that Honeycomb: The World Beyond will be showcased at Tokyo Game Show 2025, marking another key step in the title’s global debut ahead of its official global launch on November 6, 2025.

The announcement follows a successful showcase at Gamescom 2025, one of the world’s largest international gaming events with over 357,000 visitors from 128 countries. With Gamescom now concluded, Honeycomb: The World Beyond turns its focus to Tokyo Game Show, which welcomed more than 274,000 attendees in 2024 and remains one of the most influential gateways to the Asian market. Together, these events reinforce Snail’s strategy of building worldwide awareness and connecting with diverse gaming audiences ahead of launch.

At Tokyo Game Show 2025, attendees will be among the first in Asia to experience the latest pre-launch build of Honeycomb: The World Beyond, a cozy survival sandbox where players take on the role of Hennessy, a pioneering bioengineer tasked with ensuring humanity’s survival on the lush and dynamic planet of Sota7. Combining scientific experimentation, exploration, and strategic base building, the title is designed to resonate with global audiences who seek both immersive discovery and accessible gameplay.

By leveraging two of the world’s largest trade events back-to-back, Snail Games and Frozen Way Games intend to execute a coordinated global strategy designed to maximize market penetration, expand their international player base, and strengthen portfolio visibility across key regions. These activations not only highlight Honeycomb: The World Beyond’s broad appeal but also reinforce Snail Games’ commitment to scaling its reach, leveraging its proven expertise in the sandbox survival genre to expand beyond the ARK franchise, and aligning its portfolio with consumer demand in diverse global markets.

Tokyo Game Show 2025 takes place September 25–28 at Makuhari Messe in Chiba, Japan, where Honeycomb: The World Beyond will be playable at the General Exhibition Area, 06-C02.

Wishlist Honeycomb The World Beyond on Steam || Xbox || PlayStation

For creators interested in covering the game, please reach out to creatordirect@noiz.gg

Honeycomb: The World Beyond press kit

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

About Frozen Way Games frozenway.games
Frozen Way Games is a group of over 80 cheerful people with a passion for video games. Gamedev is our lifestyle and philosophy, so there’s nothing better than seeing our creations bring a lot of joy to the community.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in our public filings with the SEC and include, but are not limited to, statements regarding that the Tokyo Game Show is one of the most influential entry points to the Asian market and that Snail Games intends to execute a coordinated global strategy designed to maximize market penetration, expand its international player base, and strengthen portfolio visibility across key regions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

Release – The GEO Group Announces Contracts for Three Correctional and Rehabilitation Facilities in Florida

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GEO

September 16, 2025

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Sep. 16, 2025– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that the Florida Department of Corrections has issued Notices of Intent to Award three managed-only contracts to GEO for the assumption of management and support services at the 985-bed Bay Correctional and Rehabilitation Facility and the 1,884-bed Graceville Correctional and Rehabilitation Facility and for the continuation of management and support services at the 985-bed Moore Haven Correctional and Rehabilitation Facility.

The three contracts are expected to have an initial term of three years, effective July 1, 2026, with unlimited two-year renewal option periods. On a combined basis, the three contracts are expected to generate approximately $130 million in annualized revenues, including approximately $100 million in new incremental annualized revenues for GEO.

George C. Zoley, Executive Chairman of GEO, said, “We appreciate the confidence placed in our company by the Florida Department of Corrections. The Notices of Intent to Award these three important contracts are a testament to the high-quality support services our company has delivered in the State of Florida for over 30 years. We are particularly proud of our public-private partnership with the Florida Department of Corrections to deliver enhanced rehabilitation and post-release support services through our award-winning GEO Continuum of Care®.”

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 74,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 20,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

Pablo E. Paez (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Cadrenal Therapeutics (CVKD) – Acquisition Builds The Pipeline With Anticoagulants In Development

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, September 16, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cadrenal Acquires Complimentary Cardiovascular Products. Cadrenal announced that it has acquired the anti-coagulant assets of eXlthera Pharmaceuticals. The products include frunexian, a Pre-Phase-2 anti-coagulant drug that inhibits a different step in the coagulation cascade from tecarfarin. Frunexian is in development for different indications and could extend Cadrenal’s product line to additional indications that are not served by current drugs. The acquisition also includes an oral formulation and other research-stage molecules.

Frunexian Has Several Distinguishing Features. The lead product from eXlthera is frunexian, a Factor XIa inhibitor. Most of the DOAC (direct-acting oral anticoagulant) class target Factor Xa and have been developed for long-term use on an outpatient basis. In contrast, frunexian targets Factor XIa, a different component of the coagulation cascade.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alphabet Becomes Fourth U.S. Company Valued at $3 Trillion

Posted on by slightbourne@noblecapitalmarkets.com

Alphabet, the parent company of Google, has officially crossed the $3 trillion market capitalization threshold, becoming the fourth U.S. company to reach the milestone. Shares jumped more than 4% on Monday, propelling the tech giant into an elite group alongside Apple, Microsoft, and Nvidia.

The rally marks a historic moment for the company, which debuted on the stock market a little over 20 years ago and restructured as Alphabet a decade ago. This latest achievement comes amid heightened regulatory scrutiny, rapid advances in artificial intelligence, and intense competition in the tech sector.

Alphabet’s surge in September was fueled in large part by a favorable antitrust ruling. While a federal district court had previously found that Google held an illegal monopoly in search and advertising, the U.S. Department of Justice had pushed for harsher penalties, including a potential divestiture of the Chrome browser.

Judge Amit Mehta, however, stopped short of imposing the most severe remedies. That decision was viewed positively by investors, eliminating fears of a major breakup and giving Alphabet shares room to climb to record highs.

The judgment was celebrated not only by Wall Street but also drew national attention, with President Donald Trump publicly congratulating the company and calling it “a very good day.”

Alphabet’s $3 trillion valuation underscores its dominant role in the digital economy. The company has continued to grow despite facing challenges from emerging players in artificial intelligence, such as OpenAI and Perplexity, while also navigating increasing scrutiny from regulators in the U.S. and Europe.

CEO Sundar Pichai, who took over leadership of Alphabet in 2019, has steered the company through rapid industry change, balancing its core dominance in search and digital advertising with heavy investments in AI, cloud computing, and next-generation consumer technologies.

Alphabet’s shares are up more than 30% this year, more than double the Nasdaq’s 15% gain over the same period. The milestone reinforces its status as one of the most influential companies in the world, with billions of users relying on its products daily.

Alphabet’s achievement comes in a year when tech has dominated global markets. Nvidia, Apple, and Microsoft have all benefited from AI-driven growth, hardware innovation, and strong investor appetite for large-cap technology stocks. Alphabet’s entry into the $3 trillion club signals continued investor confidence that the company will remain at the center of technological transformation in the decade ahead.

With its valuation now cementing it as one of the world’s most valuable firms, Alphabet faces the dual challenge of maintaining growth while navigating ongoing regulatory battles and increasing competition. For investors, the latest milestone highlights both the resilience of Alphabet’s business model and its ability to adapt to a rapidly changing technology landscape.

Release – SEGG Media Highlighted with $20 Price Target in Noble Capital Markets Research Report

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SEGG

September 15, 2025

PDF Version

Independent Analysis Underscores $100 Million+ Valuation of Core Assets, Reinforcing Shareholder Value Growth Story

FORT WORTH, Texas, Sept. 15, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”), a sports, entertainment, and gaming conglomerate, today announced that Noble Capital Markets has initiated coverage of the company with an Outperform rating and a $20 price target valuing the Company at more than 4x its current market capitalization.

The report cites SEGG Media’s globally recognized brand portfolio of Sports.com, Lottery.com, Concerts.com, and TicketStub.com and the Boca Raton Sports Complex as cornerstone assets as the foundation of a valuation exceeding $100 million.

The report, now live and subject to ongoing updates, points to the Company’s transformational acquisitions and investments including Veloce Media, Quadrant, Nook, Sports.com Studios, and cutting-edge technology platforms such as Spektrum, as catalysts for accelerated valuation growth in the second half of 2025 and beyond.

Chairman and President Matthew McGahan commented:

“Independent analysis now confirms what we’ve been building: SEGG Media is dramatically undervalued relative to its assets and growth pipeline. With Sports.com, Lottery.com, and Concerts.com, we’ve created a solid three-pillar foundation, and as acquisitions close, we see significant upside in shareholder value.”

The full Noble Capital Markets research report is available at ChannelChek.

About SEGG Media Corporation

SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to: the Company’s ability to secure additional capital resources; the Company’s ability to continue as a going concern; the Company’s ability to complete acquisitions; the Company’s ability to remain in compliance with Nasdaq Listing Rules; and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

This press release was published by a CLEAR® Verified individual.

Release – GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Multi-Antigen COVID-19 Vaccine Candidate Outperforms mRNA Comparator; Enrollment Now Limited to GEO-CM04S1 Arm

ATLANTA, GA – September 15, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today showcased positive interim results for its lead COVID-19 vaccine candidate, GEO-CM04S1 at the XXI International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland.

The presentation by Alexey V. Danilov, MD, PhD, Professor, Department of Hematology and Transplantation at City of Hope, detailed data from an ongoing randomized Phase 2 trial (NCT05672355) comparing GEO-CM04S1 to a standard-of-care mRNA vaccine in patients with chronic lymphocytic leukemia (CLL).

Key Takeaways

  • Differentiated Performance: The proportion of CLL patients receiving GEO-CM04S1 that achieved the study’s primary immune endpoint met the statistical requirement to continue enrollment, while those in the mRNA COVID-19 vaccine arm did not.
  • Enrollment Shifted to GEO-CM04S1: Following interim analysis and following the recommendation of the Data Safety Monitoring Board, further enrollment is proceeding exclusively in the GEO-CM04S1 arm.
  • Durable Market Potential: CLL patients represent a high-need, underserved market where first-generation COVID-19 vaccines are often inadequate.
  • Favorable Safety Profile: Both vaccines were well tolerated, with no grade ≥3 adverse events reported.

“These data reinforce the value proposition of our multi-antigen MVA platform,” said David Dodd, Chairman & CEO of GeoVax. “Immunocompromised patients, including those with CLL, have not been adequately protected by current vaccines. GEO-CM04S1 is demonstrating the ability to overcome this gap, representing not only a clinical breakthrough but also a compelling commercial opportunity.”

About GEO-CM04S1

GEO-CM04S1 is a next-generation COVID-19 vaccine built on a Modified Vaccinia Ankara (MVA) vector. Unlike first-generation vaccines, GEO-CM04S1 encodes both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2 to drive broad, cross-variant, and durable immune protection. The vaccine is currently in three Phase 2 clinical trials:

  1. As a primary vaccine for immunocompromised patients with blood cancers or post-transplant status,
  2. As a booster in CLL patients, and
  3. As a more robust COVID-19 booster in previously mRNA-vaccinated healthy adults.

Strategic Opportunity

With millions of immunocompromised patients worldwide, including those with CLL and other hematologic malignancies, GEO-CM04S1 addresses a significant unmet medical and commercial need. The vaccine’s ability to induce nucleocapsid-specific responses sets it apart from existing single-antigen mRNA products, positioning GeoVax to lead in a multi-billion-dollar market segment where durable protection remains elusive.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

info@geovax.com

678-384-7220

Media Contact:

Jessica Starman

media@geovax.com